Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erin Richardson

Pediatric Endocrinology Des Moines, IA Medical Doctor

NPI 1447519038 CMS profile 1394200

1215 Pleasant St Ste 300, Des Moines, IA 50309

Open in the dashboard

General payments

$2,887

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Richardson of Des Moines, IA is reported in the CMS Open Payments database as having received $2,887 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,094 61
2024 General $801 43
2023 General $550 26
2022 General $397 19
2020 General $12 1
2019 General $33 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Richardson
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Erin Richardson were reported at $1,094. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Erin Richardson Pediatric Endocrinology median Middle half National median
2019 $33 $196 $68–$845 $163
2020 $12 $124 $37–$722 $114
2021 $0 $134 $35–$691 $132
2022 $397 $177 $47–$726 $149
2023 $550 $236 $75–$887 $160
2024 $801 $259 $91–$979 $164
2025 $1,094 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $506 34 payments
  2. Ascendis Pharma, Inc. $383 18 payments
  3. Novo Nordisk Inc $295 14 payments
  4. Neurocrine Biosciences, Inc. $260 12 payments
  5. Alexion Pharmaceuticals, Inc. $182 8 payments
  6. BioMarin Pharmaceutical Inc. $125 5 payments
  7. Sanofi-Aventis U.S. LLC $122 7 payments
  8. Tolmar, Inc. $104 5 payments
  9. Beta Bionics, Inc. $103 7 payments
  10. Xeris Pharmaceuticals, Inc. $101 5 payments
  11. Other $707 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,887 152 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $363 17 payments
  2. LUPRON DEPOT $275 17 payments
  3. CRENESSITY $241 11 payments
  4. STRENSIQ $182 8 payments
  5. SYNTHROID $172 12 payments
  6. Sogroya $169 7 payments
  7. FENSOLVI $128 6 payments
  8. TZIELD $106 6 payments
  9. NGENLA $97 6 payments
  10. GVOKE HYPOPEN $87 4 payments
  11. Other $1,301 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record